#### Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 4

| OSCIENT I<br>Form 4<br>March 27, 2   | PHARMACEUT   | CALS CO   | ORP   |             |  |   |   |   |               |         |  |
|--|--|---|---|-------------|--|---|---|---|---------------|---------|--|
| <b>FORM</b><br>Check t<br>if no lor<br>subject<br>Section<br>Form 4<br>Form 5<br>obligati<br>may cor<br><i>See</i> Inst<br>1(b). | SECURITIES AND EXCHANGE CO<br>Washington, D.C. 20549<br>F CHANGES IN BENEFICIAL OWNI<br>SECURITIES<br>Section 16(a) of the Securities Exchange A<br>Public Utility Holding Company Act of 1<br>of the Investment Company Act of 1940 |   |   |             |  | OMMISSIONOMB<br>Number:ERSHIP OFExpires:<br>Estimate<br>burden h<br>responseAct of 1934,<br>1935 or Section |   | •   |               |         |  |
| (Print or Type   | Responses)   |   |   |             |  |   |   |   |               |         |  |
| 1. Name and Address of Reporting Person <u>*</u><br>DellaCamera Capital Management,<br>LLC                                       |  |   |   |             |  |   |   | 5. Relationship of Reporting Person(s) to<br>Issuer<br>(Check all applicable) |               |         |  |
| (Last) (First) (Middle)<br>461 FIFTH AVENUE, 10TH<br>FLOOR   |  |   | 3. Date of Earliest Transaction(Month/Day/Year)03/25/2009 |             |  |   |   | DirectorX10% Owner<br>Officer (give title Other (specify<br>below) below)     |               |         |  |
| NEW YOF  | Filed(Month/Day/Year)  |   |   |             | 6. Individual or Joint/Group Filing(Check<br>Applicable Line)<br>_X_ Form filed by One Reporting Person<br>Form filed by More than One Reporting |   |   |   |               |         |  |
| (City)   | (State)  | (Zip)   | Tak   | la I Non    | Domizativa (   | Soonni  |   | Person  | or Donoficial | v Ownod |  |
| 1.Title of<br>Security<br>(Instr. 3)   |  | a Date 2A. Deemed 3. 4. Securities Acquired (A) 5<br>Year) Execution Date, if Transactionor Disposed of (D) S<br>any Code (Instr. 3, 4 and 5) E<br>(Month/Day/Year) (Instr. 8) (A) F<br>(A) T |   |             | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4)                               | 6.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4)                                  | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |               |         |  |
| Common<br>Stock  | 03/25/2009   |   |   | Code V<br>S | Amount<br>967,939  | (D)<br>D  | Price<br>\$<br>0.1846   | 680 594   | D (1) (2)     |         |  |
| Common<br>Stock  | 03/26/2009   |   |   | S           | 160,269  | D   | \$<br>0.1258  | 520,325   | D (1) (2)     |         |  |
| Common<br>Stock  | 03/27/2009   |   |   | S           | 200,000  | D   | \$<br>0.1302  | 320,325   | D (1) (2)     |         |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of<br/>information contained in this form are not<br/>required to respond unless the formSEC 1474<br/>(9-02)

#### Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 4

# displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | 5.<br>orNumber<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | 3                   | Date               | 7. Title<br>Amoun<br>Underl<br>Securit<br>(Instr. | nt of<br>lying                         | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Nu<br>Deriv<br>Secur<br>Bene<br>Owne<br>Follo<br>Repo<br>Trans<br>(Instr |
|---|---|---|--|---|---------------------|--------------------|---|--|---|---|
|   |   |   | Code V                                 | (A) (D)   | Date<br>Exercisable | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |   |

### **Reporting Owners**

| <b>Reporting Owner Name / Address</b>   | Relationships |           |         |       |  |  |  |
|---|---------------|-----------|---------|-------|--|--|--|
| 1   | Director      | 10% Owner | Officer | Other |  |  |  |
| DellaCamera Capital Management, LLC<br>461 FIFTH AVENUE<br>10TH FLOOR<br>NEW YORK, NY 10017 |               | Х         |         |       |  |  |  |
| Signatures  |               |           |         |       |  |  |  |
| Vincent Spinnato, Managing<br>Member  | 03/27/2009    |           |         |       |  |  |  |
| <u>**</u> Signature of Reporting Person   | Date          |           |         |       |  |  |  |
| Explanation of Responses:   |               |           |         |       |  |  |  |

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

DellaCamera Capital Management, LLC ("DCM") acts as the investment manager of the DellaCamera Capital Master Fund, Ltd. (the "Master Fund"). DellaCamera Capital Fund, Ltd. (the "Offshore Fund") is the controlling shareholder of the Master Fund. Ralph

Master Fund ): DefiaCamera, Jr., Andrew Kurtz and Vincent Spinnato are the controlling persons of DCM (collectively, Messrs. DellaCamera, Kurtz and Spinnato shall be referred to as the "Controlling Persons").

DCM, the Offshore Fund and each Controlling Person may each be deemed to indirectly beneficially own the securities reported herein(2) held by the Master Fund. For purposes of this Form 4, DCM, the Offshore Fund and each Controlling Person each disclaims ownership of the securities reported herein owned by the Master Fund, except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.